IMNN (Imunon) Research & Development : $12.96 Mil (TTM As of Sep. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Imunon Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Imunon's Research & Development for the three months ended in Sep. 2024 was $3.29 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was $12.96 Mil.

Imunon Research & Development Historical Data

The historical data trend for Imunon's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Research & Development Chart

Imunon Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

13.07

11.35

10.62

11.73

11.29

Imunon Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Research & Development	Get a 7-Day Free Trial															1.98	3.55	3.29	2.82	3.29

Imunon Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.96 Mil.

Imunon (NAS:IMNN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Imunon Research & Development Related Terms

Thank you for viewing the detailed overview of Imunon's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Imunon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (NAS:IMNN) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

0HUZ:UK CBO:Germany

Address

997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648

Website

https://www.imunon.com

Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.

Executives

Michael H Tardugno	officer: Chief Executive Offier	10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046-2364
Stacy Lindborg	director	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
James E Dentzer	director	C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Le Goff Corinne	director, officer: President and CEO	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Frederick J. Fritz	director	C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Kardaras Constantine John	officer: Chief Accounting Officer	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE100, LAWRENCEVILLE NJ 08648
Christine A Pellizzari	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Donald P Braun	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Alberto R Martinez	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Jeffrey Wayne Church	officer: Chief Financial Officer
Robert W Hooper	director	C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Andreas Voss	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Egwu, Inc. Fka Egen, Inc.	10 percent owner	601 GENOME WAY, SUITE 3400, HUNTSVILLE AL 35806
Khursheed Anwer	officer: Chief Scientific Officer	C/O CELSION CORPORATION, 997 LENOX DRVIE, SUITE 100, LAWRENCEVILLE NJ 08648
Gregory L Weaver	director	185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107